|Conditional recommendation based on very-low-quality evidence; may consider switching to a different IL-17i if the patient had had a secondary efficacy failure to current IL-17i or severe psoriasis,â€¡ or if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |
|5. Switch to an IL-12/23i biologic over adding MTX to an IL-17i biologic (PICO 40)|Very low|